TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7178675

Group type: EXPERIMENTAL
Intervention: Neo‐Biphyllin Mikroklysma (400 mg Theophylline, 600 mg Diprophylline, 600 mg Proxyphylline)
Number of subjects: 8
Study: 31376153

Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 162

Group type: COMPARATOR
Intervention: Fumaric Acid Esters (FAEs)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 162
Study: 31444714

Group type: EXPERIMENTAL
Intervention: HIV testing (open testing)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Access to HIV care
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Gender comparison
Number of subjects: 270
Study: 29943872

Group type: EXPERIMENTAL
Intervention: 6-week knee extensor training program (twice-weekly, five sets of 12 stretches, 3 seconds per stretch)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Downhill run (20 minutes)
Number of subjects: 26
Study: 26663394

Group type: EXPERIMENTAL
Intervention: Wet shaving with a razor followed by standard soap washing (SW)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Waxing followed by standard soap washing (SW)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Clipping with scissors followed by standard soap washing (SW)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard soap washing (SW) alone
Number of subjects: 30
Study: 25436819

Group type: EXPERIMENTAL
Intervention: SRH intervention in public sector HIV care clinics
Number of subjects: 197
Study: 22918392

Group type: EXPERIMENTAL
Intervention: Telephone consultation
Number of subjects: 6600

Group type: COMPARATOR
Intervention: Face-to-face consultation
Number of subjects: 6600
Study: 20018300

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 microg/kg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Thiopental (1 mg/kg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 90
Study: 17963857

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive with 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive with 30 mcg ethinyl estradiol and 3 mg drospirenone
Number of subjects: 156
Study: 16251128

Group type: EXPERIMENTAL
Intervention: Isopropyl unoprostone (group II, 1 hr before aspiration)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Isopropyl unoprostone (group III, 2 hr before aspiration)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Isopropyl unoprostone (group B, 1 hr before surgery)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Isopropyl unoprostone (group C, 2 hr before surgery)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Isopropyl unoprostone (group D, 3 hr before surgery)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Isopropyl unoprostone (group E, 4 hr before surgery)
Number of subjects: 36
Study: 12407615

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine and nimesulide combination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Epidural bupivacaine/fentanyl combination
Number of subjects: 0
Study: 10517037

Group type: EXPERIMENTAL
Intervention: Controlled-release (CR) morphine tablets (every 12 h)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Immediate-release (IR) morphine tablets (every 6 h)
Number of subjects: 18
Study: 8540930

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEPO) 150 U/kg administered intravenously twice a week for 4 weeks in group A (26 infants)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Erythrocyte transfusion when hemoglobin levels were less than 10 g/dL with symptoms or less than 8 g/dL in group B (25 infants)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Non-rHuEPO and nontransfusion group in group C (19 infants)
Number of subjects: 70
Study: 2084936

Group type: EXPERIMENTAL
Intervention: Fixed minidose warfarin (1 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (warfarin and placebo)
Number of subjects: 0
Study: 31566651

Group type: EXPERIMENTAL
Intervention: Care Ecosystem (telephone-based collaborative dementia care)
Number of subjects: 780

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 780
Study: 30422224

Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) intervention with 6 months of tailored support
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) intervention
Number of subjects: 592

Group type: COMPARATOR
Intervention: Control arm (goal setting only)
Number of subjects: 592
Study: 27381954

Group type: EXPERIMENTAL
Intervention: Integrated questions in online video lectures (Group B)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Uninterrupted online video lectures (Group A)
Number of subjects: 100
Study: 24709016

Group type: EXPERIMENTAL
Intervention: Master Your Mood (MYM) online group course
Number of subjects: 234
Study: 22293059

Group type: EXPERIMENTAL
Intervention: Alfacalcidol
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Paricalcitol
Number of subjects: 80

Group type: COMPARATOR
Intervention: Alfacalcidol and Paricalcitol
Number of subjects: 80
Study: 19797501

Group type: EXPERIMENTAL
Intervention: 1 microg ACTH (1‐24) administered in the morning
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1 microg ACTH (1‐24) administered in the afternoon
Number of subjects: 60
Study: 17237126

Group type: EXPERIMENTAL
Intervention: Conventional output SCS (3 x 2 h/day, phase A)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Conventional output SCS (24 h/day, phase B)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Subthreshold output SCS (3 x 2 h/day, phase C)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low-output (placebo) SCS (24 h/day, phase D)
Number of subjects: 12
Study: 15924803

Group type: EXPERIMENTAL
Intervention: Xuezhikang (0.6 g Bid)
Number of subjects: 4870
Study: 11978847

Group type: EXPERIMENTAL
Intervention: [11C]NNC 112 (D1 receptor antagonist)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 32
Study: 9621761

Group type: EXPERIMENTAL
Intervention: Physical activity at the workplace
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 7649665

Group type: EXPERIMENTAL
Intervention: Terminalia Arjuna (500 mg 8-hourly)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2704583

Group type: EXPERIMENTAL
Intervention: Caffeine (10 mg/kg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 362141

Group type: EXPERIMENTAL
Intervention: RA27/3 rubella vaccine (Almevax)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cendehill vaccine (Cedevax)
Number of subjects: 0
Study: 31504897

Group type: EXPERIMENTAL
Intervention: Family‐centered intervention program (FCIP)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Usual care program (UCP)
Number of subjects: 251
Study: 29029224

Group type: EXPERIMENTAL
Intervention: HZ/su vaccine coadministered with IIV4
Number of subjects: 828

Group type: COMPARATOR
Intervention: Control group receiving IIV4 followed by HZ/su
Number of subjects: 828
Study: 25516405

Group type: EXPERIMENTAL
Intervention: Exercise intervention with DVD and written materials
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Exercise intervention with social support groups
Number of subjects: 261

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 261
Study: 23991916

Group type: EXPERIMENTAL
Intervention: Post-transplantation anemia (PTA)
Number of subjects: 2102
Study: 22013790

Group type: EXPERIMENTAL
Intervention: Dengzhan Xixin Injection + Chinese decoction + Dengzhan Shengmai Capsule + acupuncture + massage + external washing with Chinese medicine
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Kudiezi Injection + Chinese decoction + Naoshuantong Capsule + acupuncture + massage + external washing with Chinese medicine
Number of subjects: 99

Group type: COMPARATOR
Intervention: Western medicine control (rehabilitation training and electronic stimulus)
Number of subjects: 99
Study: 18203894

Group type: EXPERIMENTAL
Intervention: 2 g UHV-HPMC
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 1 g HV-HPMC
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 2 g HV-HPMC
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 4 g MC
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (2 g cellulose)
Number of subjects: 50
Study: 15831351

Group type: EXPERIMENTAL
Intervention: Gastric bypass surgery
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (normal BP rhythm)
Number of subjects: 8
Study: 12143264

Group type: EXPERIMENTAL
Intervention: Clopidogrel (Plavix)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study: 10521098

Group type: EXPERIMENTAL
Intervention: Single IUI 34 hours after hCG administration (Group A)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Double IUI 12 hours and 34 hours after hCG administration (Group B)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Double IUI 34 hours and 60 hours after hCG administration (Group C)
Number of subjects: 273
Study: 8622099

Group type: EXPERIMENTAL
Intervention: Isepamicin once daily plus ceftriaxone
Number of subjects: 235

Group type: COMPARATOR
Intervention: Amikacin twice daily plus ceftriaxone
Number of subjects: 235
Study: 1828561

Group type: EXPERIMENTAL
Intervention: Folic acid (3 mg daily for 16 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lactose (placebo, 3 mg daily for 16 weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (Folic acid and Lactose)
Number of subjects: 20
Study: 6966835

Group type: EXPERIMENTAL
Intervention: Antacids
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 77
Study: 31699517

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (0.4 mEq per kg of ideal body weight per day) (n=74)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Identical‐appearing placebo (n=75)
Number of subjects: 149
Study: 29306619

Group type: EXPERIMENTAL
Intervention: 500 mL of glucose 10% (50 g glucose)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 100 mL of 2% lipid emulsion (soybean 30%, medium chain triglycerides (TG) 30%, olive oil 25%, fish oil 15%, and 20 mg vitamin E)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Conventional preoperative fasting (C group)
Number of subjects: 63
Study: 27628940

Group type: EXPERIMENTAL
Intervention: PEERS® for Young Adults intervention
Number of subjects: 56
Study: 25676122

Group type: EXPERIMENTAL
Intervention: s-ketamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 23937849

Group type: EXPERIMENTAL
Intervention: Felodipine and Perindopril
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Indapamide sustained release tablets and Perindopril
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study: 20065611

Group type: COMPARATOR
Intervention: Never-smokers
Number of subjects: 724

Group type: COMPARATOR
Intervention: Ex-smokers
Number of subjects: 724

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 724

Group type: EXPERIMENTAL
Intervention: Heavy-smokers (≥30 pack x year)
Number of subjects: 724

Group type: EXPERIMENTAL
Intervention: Light-smokers (<30 pack x year)
Number of subjects: 724
Study: 19058658

Group type: EXPERIMENTAL
Intervention: Displays of moral credentials
Number of subjects: 0
Study: 17083353

Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum BB536
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 15325873

Group type: EXPERIMENTAL
Intervention: Ground coverings/barriers plus raised garden bed (RB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ground coverings/barriers only (no raised bed, NRB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 11104589

Group type: EXPERIMENTAL
Intervention: Alanyl-glutamine supplementation (0.5 g/kg BW/day)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard isonitrogenous, isoenergetic TPN
Number of subjects: 37
Study: 9046717

Group type: EXPERIMENTAL
Intervention: Ketoprofen 100 mg intramuscularly
Number of subjects: 64

Group type: COMPARATOR
Intervention: Paracetamol 500 mg intramuscularly
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 64
Study: 8314685

Group type: EXPERIMENTAL
Intervention: Pravastatin 20-40 mg/day given at bedtime
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 3089202

Group type: EXPERIMENTAL
Intervention: Clobazam
Number of subjects: 20
Study: 31352467

Group type: EXPERIMENTAL
Intervention: Exposure therapy (n=25; female/male=24/1)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Progressive muscle relaxation (PMR; n=20; female/male=17/3)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Exposure therapy
Number of subjects: 45
Study: 30022470

Group type: EXPERIMENTAL
Intervention: Thyroid autoimmune disease patients
Number of subjects: 357

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 357
Study: 26413774

Group type: EXPERIMENTAL
Intervention: Sitting for one hour per day for five consecutive days
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standing for one hour per day for five consecutive days
Number of subjects: 36
Study: 24872002

Group type: EXPERIMENTAL
Intervention: Gadobutrol (0.1 mmol/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Gadobenate dimeglumine (0.1 mmol/kg)
Number of subjects: 20
Study: 23098346

Group type: EXPERIMENTAL
Intervention: Losartan 12.5 mg
Number of subjects: 9948

Group type: EXPERIMENTAL
Intervention: Losartan 25 mg
Number of subjects: 9948

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 9948

Group type: EXPERIMENTAL
Intervention: Losartan 100 mg
Number of subjects: 9948

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg / Hydrochlorothiazide 12.5 mg
Number of subjects: 9948

Group type: EXPERIMENTAL
Intervention: Losartan 100 mg / Hydrochlorothiazide 25 mg
Number of subjects: 9948

Group type: COMPARATOR
Intervention: Control group (Losartan 100 mg/Hydrochlorothiazide 25 mg)
Number of subjects: 9948
Study: 20631555

Group type: EXPERIMENTAL
Intervention: 10‐mg aripiprazole for 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 0
Study: 18346606

Group type: EXPERIMENTAL
Intervention: Erythromycin 250 mg and placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Erythromycin 250 mg and ranitidine 150 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg and metoclopramide 10 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 15934081

Group type: EXPERIMENTAL
Intervention: Continuous treatment with NSAIDs
Number of subjects: 215

Group type: COMPARATOR
Intervention: On-demand treatment with NSAIDs
Number of subjects: 215
Study: 12870201

Group type: EXPERIMENTAL
Intervention: Flutrimazole 1% powder applied twice daily for 4 weeks
Number of subjects: 222

Group type: COMPARATOR
Intervention: Bifonazole 1% powder applied twice daily for 4 weeks
Number of subjects: 222
Study: 10895107

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (two oral supplements each day during hospital stay)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (no nutritional supplementation)
Number of subjects: 84
Study: 8792511

Group type: EXPERIMENTAL
Intervention: Dapsone
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2

Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 2

Group type: COMPARATOR
Intervention: Hydroxychloroquine
Number of subjects: 2
Study: 1541318

Group type: EXPERIMENTAL
Intervention: Pinacidil (25 to 100 mg daily for 8 weeks)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 2988337

Group type: EXPERIMENTAL
Intervention: Methotrexate-leucovorin rescue plus Cytoxan
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-fluorouracil plus Cytoxan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Melphalan or actinomycin D-5-fluorouracil-Cytoxan
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-fluorouracil-Cytoxan
Number of subjects: 0
Study: 29504471

Group type: EXPERIMENTAL
Intervention: Transanal hemorrhoidal dearterialization (THD)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Stapled hemorrhoidopexy (SH)
Number of subjects: 100
Study: 27377404

Group type: EXPERIMENTAL
Intervention: Practice Facilitation (PF) for one year including onsite visits and shared learning
Number of subjects: 250

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 250
Study: 22878539

Group type: EXPERIMENTAL
Intervention: Intramuscular injection into neck area
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intramuscular injection into thigh muscle
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous injection
Number of subjects: 0
Study: 21098510

Group type: EXPERIMENTAL
Intervention: Vitamin C (ascorbic acid) preoperatively and postoperatively (Group A, n=85)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control group (no vitamin C, Group B, n=85)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Vitamin C group (Group A)
Number of subjects: 170
Study: 19318448

Group type: EXPERIMENTAL
Intervention: DHEA 50 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 17261985

Group type: COMPARATOR
Intervention: Vibration only (Group 3)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Vibration exercise (Group 1)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Exercise only (Group 2)
Number of subjects: 45
Study: 15520361

Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 11405173

Group type: EXPERIMENTAL
Intervention: Combined adjuvant 5‐fluorouracil‐based chemotherapy and radiotherapy
Number of subjects: 236
Study: 9272360

Group type: EXPERIMENTAL
Intervention: Acellular vaccines (Chiron Biocine three-component and SmithKline Beecham three-component)
Number of subjects: 1275

Group type: EXPERIMENTAL
Intervention: Whole-cell study vaccine (produced by Connaught Laboratories, Inc.)
Number of subjects: 1275
Study: 7944455

Group type: EXPERIMENTAL
Intervention: Intra-lymph nodal injection of MMC-CH 40
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 95
Study: 3277804

Group type: EXPERIMENTAL
Intervention: Nebulized terbutaline (10 mg)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Intravenous enprofylline (2 mg/kg)
Number of subjects: 69
Study: 29131414

Group type: EXPERIMENTAL
Intervention: OHIP-5 score of 3 or higher on at least two of the five items
Number of subjects: 3500
Study: 29194244

Group type: EXPERIMENTAL
Intervention: Simulation experience during postpartum hemorrhage scenario
Number of subjects: 7
Study: 25678546

Group type: EXPERIMENTAL
Intervention: High-intensity training (10 min warm-up followed by 4×4 min intervals at ∼90% of peak heart rate)
Number of subjects: 1567

Group type: EXPERIMENTAL
Intervention: Moderate-intensity training (50 min of continuous work at ∼70% of peak heart rate)
Number of subjects: 1567

Group type: COMPARATOR
Intervention: Control group following physical activity advice according to national recommendations
Number of subjects: 1567
Study: 23117243

Group type: EXPERIMENTAL
Intervention: Glucocorticoid (GC) bridging therapy response at 2 weeks
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Induction therapy arms and baseline DAS
Number of subjects: 120
Study: 21402164

Group type: EXPERIMENTAL
Intervention: 100 mg D-cycloserine (DCS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 400 mg valproic acid (VPA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of 100 mg DCS and 400 mg VPA
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 18303228

Group type: EXPERIMENTAL
Intervention: Bimatoprost
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Travoprost
Number of subjects: 82
Study: 21949042

Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Trivalent inactivated vaccine (TIV)
Number of subjects: 55
Study: 15635596

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with newer agents (e.g., taxanes)
Number of subjects: 0
Study: 12377810

Group type: EXPERIMENTAL
Intervention: Hypnotic relaxation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Anger
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Happiness
Number of subjects: 20

Group type: COMPARATOR
Intervention: Awake (control)
Number of subjects: 20
Study: 10518858

Group type: EXPERIMENTAL
Intervention: Herbal Mouth and Gum Therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (distilled water and dye)
Number of subjects: 40
Study: 8124953

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: IL‐1ra 17 mg/hr
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: IL‐1ra 67 mg/hr
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: IL‐1ra 133 mg/hr
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: IL‐1ra treatment in septic shock
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: IL‐1ra treatment in Gram-negative infection
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: IL‐1ra treatment in patients with IL‐6 > 100 pg/mL
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: IL‐1ra treatment
Number of subjects: 99
Study: 2536789

Group type: EXPERIMENTAL
Intervention: Three doses of RIT 4237 attenuated rotavirus vaccine
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: One dose of RIT 4237 attenuated rotavirus vaccine
Number of subjects: 391
Study: 12824829

Group type: EXPERIMENTAL
Intervention: Laser treatment
Number of subjects: 121

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 121
Study: 31569256

Group type: EXPERIMENTAL
Intervention: REVISE ACL Classification using CT scan analysis
Number of subjects: 10
Study: 31735538

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedD) and increased physical activity for 12 months
Number of subjects: 68

Group type: COMPARATOR
Intervention: Usual care control group (CG)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 68